Dr Phil Jones
Epidermal stem cells
Wellcome Trust Sanger Institute
The Jones Group uses transgenic models, advanced imaging, novel sequencing approaches and quantitative methods to define the critical evolutionary steps that lead to non-melanoma skin and oesophageal cancer, and test the ability of targeted therapies to reduce the risk of cancer development.
Current projects include:
- Mapping mutations in normal human tissues
- Modelling clonal evolution in pre-cancer
Phil Jones is Leader of the “Stem cells and Cancer” programme, MRC Cancer Cell Unit and is also a Consultant in Medical Oncology at Addenbrooke’s Hospital.